摘要
目的探讨急性白血病免疫分型对判断预后的指导意义。方法采用流式细胞仪(FCM)对32例急性白血病进行免疫分型。初诊的急性非淋巴细胞性白血病(AML)分别予CAG,HCAG,DA(3+7)标准方案化疗,急性淋巴细胞性白血病(ALL)予DOP或DOLP方案化疗,杂合性白血病(ABL)予DOAP方案化疗。结果AML患者常见表达抗原依次为CD13>CD33>CD117>CD38>HLA-DR>CD34>CD64>CD14>CD56>CD7,B系ALL主要表达抗原为CD10,CD19及非特异性祖系抗原HLA-DR,T系ALL主要表达抗原为CD7,CD5和髓系CD13以及非特异性祖系抗原CD38。急淋(My+ALL)和急非淋(Ly+AML)预后较差。结论白血病免疫分型为制订治疗方案和判断预后提供了重要依据。
Objective To analyse the significance of immunological classification in estimating prognosis. Methods （1） Immunophenotypes were examined by FCM in 32 cases of acute leukemia（AL）. （2）Regimen DA, CAG or HCAG was conducted in the patients with AML. Regimen DOP or DOLP was conducted in the patients with ALL. Regimen DOAP was conducted in the patients with ABL. Results （ 1 ） Myeloblastic agents were often expressed as follows ： CD13, CD33, CD117, CD38, HLA - DR, CD34, CD64, CD14, CD56, CD7 in order of decreasing level. （2） CD16, CD19, HLA-DR agents were highly expressed in B lymphoblastic. （3）CD7,CD5,CD13,CD38 agents were highly expressed in T lymphoblastic. （4）My ＋ALL and Ly ＋ AML had a poor prognosis. Conclusion Immunological classification has important value in therapy and prognosis of AL.
出处
《中国药业》
CAS
2009年第1期55-57,共3页
China Pharmaceuticals
关键词
急性白血病
免疫分型
预后
acute leukemia
immunophenotype
prognosis
